2 1st Quarter Clinical Services Revenue per Test • 8th Consecutive Quarter of Revenue per Test Growth • Revenue per Test Increased 8% over Prior Year to $402 • Focused on Higher-Value Tests • Positive Contributions from Strategic Reimbursement Initiatives Q2 Q3 Q4 Q1 • Gross Margin Improved 620 bps, representing the Third Consecutive Quarter of 500 bps+ of Improvement • Revenue: Highest Revenue Growth by Quarter Since Q2 of 2021. Drivers are increases in revenue per test, volume and Pharma Services revenue. ...